Fig. 1From: Are patients with high-risk polycythemia vera receiving cytoreductive medications? A retrospective analysis of real-world dataGuidelines for the treatment of low- and high-risk* patients with PV [6, 7]. *Patients with high-risk PV are ≥ 60 years of age and/or have a history of thrombotic events. AML acute myeloid leukemia, MF myelofibrosis, PV polycythemia veraBack to article page